Finding A Cure In Dna?
The British company PPL Therapeutics PLC, which holds the rights to the controversial sheep-cloning technology, saw its stock jump with the arrival of Dolly on the world stage. But it is far from clear whether PPL will profit from its technology. Researchers say it is too early to know exactly what the commercial applications will be.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.